UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 1, 2018
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At August 6, 2018, 5,862,109,503 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and six months ended July 1, 2018 and July 2, 2017
Condensed Consolidated Statements of Comprehensive Income for the three and six months ended July 1, 2018 and July 2, 2017
Condensed Consolidated Balance Sheets as of July 1, 2018 and December 31, 2017
Condensed Consolidated Statements of Cash Flows for the six months ended July 1, 2018 and July 2, 2017
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
52
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
53
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
113
Item 4.
Controls and Procedures
113
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
114
Item 1A.
Risk Factors
114
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
115
Item 3.
Defaults Upon Senior Securities
115
Item 4.
Mine Safety Disclosures
115
Item 5.
Other Information
115
Item 6.
Exhibits
116
Signature
117
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2017 Financial Report
Financial Report for the fiscal year ended December 31, 2017, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017
2017 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2017
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
AMPA
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Avillion
Avillion LLP
Biogen
Biogen Inc.
BMS
Bristol-Myers Squibb Company
BRCA
BReast CAncer susceptibility gene
CAR T
chimeric antigen receptor T cell
CDC
U.S. Centers for Disease Control and Prevention
Cellectis
Cellectis S.A.
CIAS
cognitive impairment associated with schizophrenia
Citibank
Citibank, N.A.
CML
chronic myelogenous leukemia
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson Corp.
King
King Pharmaceuticals, Inc.
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel Cell Carcinoma
MCO
Managed Care Organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation, Inc.
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NovaQuest
NovaQuest Co-Investment Fund V, L.P.
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
Pharmacy Benefit Manager
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended July 1, 2018
RCC
renal cell carcinoma
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
Servier
Les Laboratoires Servier SAS
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SIP
Sterile Injectable Pharmaceuticals
S&P
Standard and Poor s
StratCO
Strategy and Commercial Operations
Tax Cuts and Jobs Act or TCJA
Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Teuto
Laborat rio Teuto Brasileiro S.A.
U.K.
United Kingdom
U.S.
United States
VAI
Voluntary Action Indicated
ViiV
ViiV Healthcare Limited
WRD
Worldwide Research and Development
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
July 1,
2018
July 2,
2017
July 1,
2018
July 2,
2017
Revenues
13,466
12,896
26,373
25,675
Costs and expenses:
Cost of sales(a)
2,916
2,660
5,479
5,128
Selling, informational and administrative expenses(a)
3,542
3,430
6,954
6,745
Research and development expenses(a)
1,797
1,787
3,540
3,502
Amortization of intangible assets
1,191
1,208
2,387
2,394
Restructuring charges and certain acquisition-related costs
44
70
87
153
Other (income)/deductions net
(551
(75
(728
(14
Income from continuing operations before provision for taxes on income
4,527
3,815
8,654
7,767
Provision for taxes on income
648
739
1,204
1,560
Income from continuing operations
3,879
3,077
7,450
6,207
Discontinued operations net of tax
(1
Net income before allocation to noncontrolling interests
3,879
3,078
7,449
6,208
Less: Net income attributable to noncontrolling interests
16
14
Net income attributable to Pfizer Inc.
3,872
3,073
7,432
6,194
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.66
0.52
1.26
1.04
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.66
0.52
1.26
1.04
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.65
0.51
1.24
1.02
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.65
0.51
1.24
1.02
Weighted-average shares basic
5,866
5,958
5,911
5,982
Weighted-average shares diluted
5,952
6,037
6,004
6,065
Cash dividends paid per common share
0.34
0.32
0.68
0.64
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(MILLIONS OF DOLLARS)
July 1,
2018
July 2,
2017
July 1,
2018
July 2,
2017
Net income before allocation to noncontrolling interests
3,879
3,078
7,449
6,208
Foreign currency translation adjustments, net
(699
247
59
474
Reclassification adjustments
(35
111
(20
112
(734
358
39
586
Unrealized holding gains/(losses) on derivative financial instruments, net
127
(90
13
(99
Reclassification adjustments for (gains)/losses included in net income(a)
310
(208
354
(449
437
(297
367
(548
Unrealized holding gains/(losses) on available-for-sale securities, net
(374
164
(214
314
Reclassification adjustments for (gains)/losses included in net income(a)
143
(40
(31
97
Reclassification adjustments for unrealized gains included in Retained earnings(b)
(462
(231
124
(707
412
Benefit plans: actuarial gains/(losses), net
(57
61
106
62
Reclassification adjustments related to amortization
61
145
123
308
Reclassification adjustments related to settlements, net
30
(1
67
51
Other
107
(80
21
(35
141
124
316
385
Benefit plans: prior service costs and other, net
(2
(2
Reclassification adjustments related to amortization
(46
(46
(92
(91
Reclassification adjustments related to curtailments, net
(7
(4
(13
(11
Other
(1
(53
(52
(104
(104
Other comprehensive income/(loss), before tax
(440
258
(88
732
Tax provision/(benefit) on other comprehensive income/(loss)
173
(163
605
(138
Other comprehensive income/(loss) before allocation to noncontrolling interests
(613
421
(693
870
Comprehensive income before allocation to noncontrolling interests
3,266
3,499
6,755
7,078
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(4
13
29
Comprehensive income attributable to Pfizer Inc.
3,270
3,486
6,750
7,049
(a)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(b)
For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
July 1,
2018
December 31,
2017
(Unaudited)
Assets
Cash and cash equivalents
2,704
1,342
Short-term investments
10,727
18,650
Trade accounts receivable, less allowance for doubtful accounts: 2018 $578; 2017 $584
9,873
8,221
Inventories
8,074
7,578
Current tax assets
3,582
3,050
Other current assets
2,343
2,301
Total current assets
37,303
41,141
Long-term investments
6,595
7,015
Property, plant and equipment, less accumulated depreciation: 2018 $16,844; 2017 $16,172
13,919
13,865
Identifiable intangible assets, less accumulated amortization
46,584
48,741
Goodwill
55,836
55,952
Noncurrent deferred tax assets and other noncurrent tax assets
1,848
1,855
Other noncurrent assets
2,896
3,227
Total assets
164,980
171,797
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2018 $4,262; 2017 $3,546
11,583
9,953
Trade accounts payable
4,196
4,656
Dividends payable
1,980
2,029
Income taxes payable
2,481
477
Accrued compensation and related items
1,791
2,196
Other current liabilities
10,125
11,115
Total current liabilities
32,156
30,427
Long-term debt
28,935
33,538
Pension benefit obligations, net
5,006
5,926
Postretirement benefit obligations, net
1,473
1,504
Noncurrent deferred tax liabilities
5,743
3,900
Other taxes payable
15,597
18,697
Other noncurrent liabilities
5,947
6,149
Total liabilities
94,856
100,141
Commitments and Contingencies
Preferred stock
20
21
Common stock
465
464
Additional paid-in capital
84,898
84,278
Treasury stock
(95,463
(89,425
Retained earnings
89,860
85,291
Accumulated other comprehensive loss
(10,003
(9,321
Total Pfizer Inc. shareholders equity
69,778
71,308
Equity attributable to noncontrolling interests
346
348
Total equity
70,124
71,656
Total liabilities and equity
164,980
171,797
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(MILLIONS OF DOLLARS)
July 1,
2018
July 2,
2017
Operating Activities
Net income before allocation to noncontrolling interests
7,449
6,208
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
3,129
3,129
Asset write-offs and impairments
41
97
Adjustments to loss on sale of HIS net assets
64
TCJA impact(a)
(68
Deferred taxes from continuing operations
(500
320
Share-based compensation expense
379
388
Benefit plan contributions in excess of expense
(826
(1,079
Other adjustments, net
(523
(458
Other changes in assets and liabilities, net of acquisitions and divestitures
(3,250
(3,844
Net cash provided by operating activities
5,830
4,824
Investing Activities
Purchases of property, plant and equipment
(810
(806
Purchases of short-term investments
(3,122
(2,394
Proceeds from redemptions/sales of short-term investments
10,497
3,517
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
1,231
3,424
Purchases of long-term investments
(1,070
(1,663
Proceeds from redemptions/sales of long-term investments
1,361
1,538
Acquisitions of businesses, net of cash acquired
(1,000
Acquisitions of intangible assets
(32
(41
Other investing activities, net
138
455
Net cash provided by investing activities
8,193
3,030
Financing Activities
Proceeds from short-term borrowings
1,746
4,799
Principal payments on short-term borrowings
(2,921
(5,088
Net proceeds from short-term borrowings with original maturities of three months or less
2,092
265
Proceeds from issuance of long-term debt
5,273
Principal payments on long-term debt
(3,104
(4,473
Purchases of common stock
(6,063
(5,000
Cash dividends paid
(4,021
(3,855
Proceeds from exercise of stock options
474
411
Other financing activities, net
(831
(228
Net cash used in financing activities
(12,628
(7,896
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(15
37
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents
1,381
(5
Cash and cash equivalents and restricted cash and cash equivalents, beginning
1,431
2,666
Cash and cash equivalents and restricted cash and cash equivalents, end
2,811
2,661
Supplemental Cash Flow Information
Non-cash transactions:
Receipt of ICU Medical common stock(b)
428
Promissory note from ICU Medical(b)
75
Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets(b)
92
Cash paid (received) during the period for:
Income taxes
1,197
1,121
Interest
724
881
Interest rate hedges
(71
(226
(a)
As a result of the enactment of the TCJA in December 2017, Pfizer s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.
(b)
For additional information, see Note 2B. Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment: Divestitures.